Liang You, Ph.D.

Associate Professor of Surgery
Division of Adult Cardiothoracic Surgery

Contact Information

2340 Sutter Street N-221, Box 1724
University of California, San Francisco
San Francisco, CA 94143-1724
(415) 476-6906 Phone
liang.you@ucsfmedctr.org
Open Popup
  • 1982-87, Jinzhou Medical College, Jinzhou, P.R.C., M.D. , Medicine
  • 1988-94, Medical College of Ohio, Toledo, Ohio, Ph.D., Pathology
  • 1997-2002, UCSF, Staff Research Associate, Dept. of Surgery, UCSF Comprehensive Cancer Center
  • Thoracic Oncology Program
  • Thoracic Oncology Laboratory
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Akt Signaling Pathway
  • Human cancer genetics and epigenetics
  • Lung cancer and mesothelioma
  • Molecular analysis on matched normal/tumor tissues
  • Small molecules, antibodies and recombinant proteins
  • Wnt Signaling Pathway

Dr. Liang You received his M.D. in 1987 from the Jinzhou Medical College in China and his Ph.D. in pathology from the Medical College of Ohio in 1994. He began work at UCSF in the thoracic oncology laboratory after work at the National Cancer Institute. At UCSF, Dr. You has made a significant impact on lung cancer and mesothelioma research. Most notably, he has been been instrumental in helping Dr. David Jablons mold a fledgling research effort into a thriving molecular genomics laboratory, an integral part of the Comprehensive Cancer Center and nationally recognized.

In November 2007, Dr. You was presented with the David Jablons "Asclepios" Award by the Bonnie J. Addario Lung Cancer Foundation for his pioneering research.

Dr. You has been a creative and dynamic force in the lab and his work has led to numerous discoveries. He helped demonstrate the relationship of p14ARF tumor suppressor deletions to the p53 pathway in mesothelioma and the effects of oncolytic viruses upon these tumors. He also discovered several novel mechanisms for the activation of upstream WNT pathways.

Dr. You has helped identify several novel biomarkers and therapeutic targets in lung cancer and mesothelioma. He and his colleagues demonstrated overexpression of Dishevelled-3 and silencing of SFRP-2, SOCS-3 and WIF-1 through promoter methylation. Dr. You and chemist Dr. Naoaki Fujii developed a small molecule Wnt pathway inhibitor, FJ9, that disrupts the interaction between the Frizzled receptor and Dishevelled, a Wnt signal transducer.

Dr. You is currently investigating the use of recombinant human WIF-1 protein as a cancer therapy and seeking out new therapeutic targets and novel interventions. 

  1. You, L., He, B., Uematsu, K., Xu, Z., Mazieres, J., Lee, A., McCormick, F., and Jablons D.M. Inhibition of Wnt-1 signaling induces apoptosis in b-catenin-deficient mesothelioma cells. Cancer Research, 2004 May 15;64(10):3474-8.
    Role: generated initial idea, developed study, generated initial data and some experimental data, supervised work, wrote paper
  2. You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F, Jablons DM. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene. 2004 Aug 12;23(36):6170-4.
    Role: generated initial idea, developed study, generated initial data and some experimental data, supervised work, wrote paper.
  3. Mazieres J, L. You, B. He, Z. Xu, A. Lee, I. Mikami, F. McCormick and D.M. Jablons. Inhibition of Wnt16 in human leukemia cells containing the t(1;19) translocation induces apoptosis, Oncogene, 2005. 24(34):5396-400.
    Role: generated initial idea, developed study, generated initial data and some experimental data, supervised work, wrote paper
  4. Kim J, You L, Xu Z, Kuchenbecker K, Raz D, He B, Jablons D.  Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg. 2007 Mar;133(3):733-7
    Role: generated initial idea, developed study, generated initial data and some experimental data, supervised work, wrote paper.
  5. Fujii N, You L, Xu Z, Uematsu K, Shan J, He B, Mikami I, Edmondson LR, Neale G, Zheng J, Guy RK, Jablons DM.  An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res. 2007 Jan 15;67(2):573-9 
    Role: generated initial idea, developed study, generated initial data and some experimental data, supervised work, wrote paper.

View all Publications

X